| Peer-Reviewed

Effect of Streptomyces sp 3400 JX826625 Metabolites on Multidrug Resistant Candida albicans Development and Chemical Characterization of Antifungal Metabolites

Received: 8 November 2019     Accepted: 26 November 2019     Published: 4 December 2019
Views:       Downloads:
Abstract

The search of new antimicrobial metabolites remains until now an alternative to mitigate concerns caused by antimicrobial resistance. This work aims to demonstrate the ability of actinomycete strain (Streptomyces sp 3400 JX826625) to inhibit pathogen yeast growth (Candida albicans), isolated from a woman infected by recidivate candidiasis and to reveal chemical characteristics of the antifungal metabolites produced. Antifungal test using cylinder agar technique showed that the yeast pathogen was resistant to the nystatin 100.000 and the ketoconazole 50 while Streptomyces sp 3400 displayed activity with 25mm of inhibition zone diameter. The optimization of antifungal production parameters by the strain recapitulates that its culture on sporulation agar medium at a pH=5,13, incubated at 30°C for 7 days promoted the activity of the actinomycete; the butanol was the best solvent for antifungal metabolites extraction. Chemical investigation showed that liquid-liquid fractionation method of crude extract allowed to obtain four fractions (hexane, dichloromethane, butanol and aqueous fractions) in which butanol fraction exhibited the best antifungal activity (19mm) according to antifungal test by disk method. Separation of active compounds from this active fraction by TLC method revealed 10 bands and its bioautography showed two active compounds against the pathogen yeast of which the diameters of inhibition zone were 19mm and 10mm, respectively. Chemical screening of the butanolic fraction revealed the presence of terpenes, alkaloids, coumarins and anthracene derivatives family with colorimetry by TLC method. The recovering of active compounds by TLC preparative gave two methanolic fractions (MF1 and MF2) of which MIC and MFC were respectively 1,562µg/ml and 3,625µg/ml for MF1; 17µg/ml and 34µg/ml for MF2. The two compounds were stable in a range of temperature from 19°C to 46°C; however, a best antifungal activity was recorded at -20°C. UV- visible spectra of the two active compounds revealed that Streptomyces sp 3400 contained non-polyene and heptaene group of polyene molecules.

Published in American Journal of Biomedical and Life Sciences (Volume 7, Issue 6)
DOI 10.11648/j.ajbls.20190706.17
Page(s) 164-173
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2019. Published by Science Publishing Group

Keywords

Streptomyces sp 3400, Candida albicans, Antifungals, Polyene, Non-polyene

References
[1] Pfaller M. A., Diekema D. J., (2007). Epidemiology of invasive candidiasis: A persistent public health problem. Clinical Microbiology Reviews, 20: 133-163.
[2] Ryan K. J. (2004). Candida, Aspergillus, and Other Opportunistic Fungi. In: Ryan K. J. and Ray C. G. Sherris Medical Microbiology, USA: Mc Graw-Hill, 4: 659-668.
[3] Odds F. C. (2010). Molecular phylogenetics and epidemiology of Candida albicans. Future Microbiology, 5 (1): 67-79.
[4] Schell W. A. (2006). Mycotic agents of human disease. In: Fleming D. O. and Hunt D. L. Biological Safety: Principles and Practises. Washington D. C: ASM Press, 4: 163-178.
[5] Arendrup M. C., Patterson T. F. (2017). Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment. J Infect Dis. 216 (3): S445-S451.
[6] Ruhnke M. (2006). Epidemiology of Candida albicans infections and role of non- Candida albicans yeasts. Current Drug Targets, 7 (4): 495-504.
[7] Ben-Ami R., Olshtain-Pops K., Krieger M. et al. (2012). Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrobial agents and chemotherapy; 56: 2518-23.
[8] Ahmed Nafis, Najoua Elhidar, Brahim Oubaha, Salah Eddine Samri, Timo Niedermeyer, Yedir Ouhdouch, Lahcen Hassani and Mustapha Barakate. (2018). Screening for Non-polyenic Antifungal Produced by Actinobacteria from Moroccan Habitats: Assessment of Antimycin A19 Production by Streptomyces albidoflavus AS25. International Journal of Molecular and Cellular Medicine, 7 (2): 133-145.
[9] Andriambeloson O., Rasolomampianina R. and Raherimandimby M. (2014). Selection and characterization of bioactive actinomycetes associated with the medicinal plant Ginger (Zingiber officinale). Journal of International Academic Research for Multidisciplinary. 2 (9): 30-45.
[10] Herivony Onja Andriambeloson, Rado Rasolomampianina, Rahanira Ralambondrahety, Rigobert Andrianantenaina, Marson Raherimandimby, Fidèle Randriamiharisoa. (2016). Biological Potentials of Ginger Associated Streptomyces Compared with Ginger Essential Oil. American Journal of Life Sciences. 4 (6): 152-163.
[11] Veron B. (2013). Etude de la sensibilité des champignons aux antifongiques, antifongigramme par la méthode de diffusion en milieu gélosé. www.microbiologie-médicale.fr/mycologie/antifongigramme.htm.
[12] Lindenfelser L. A., Shotwell O. L., Bachler M. J., Shanon G. M., Pridham T. G. (1964). Antibiotics against plant disease VIII. Screening for nonpolyenic antifungal antibiotics produced by streptomycetes. Applied Microbiology, 12: 508-512.
[13] Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT et al. (2012). Candida spp with acquired echinocandin resistance, France, 2004-2010. Emerging Infectious Diseases, 8: 86-90.
[14] Perlin D. S. (2014). Echinocandin resistance, susceptigbility testing and prophylaxis: implications for patient management. Drugs, 74: 1573-85.
[15] Guillot J. and Dannaoui E. (2015). Resistance to antifungal drugs: importance in human and veterinary medicine. Bulletin de l’Académie Vétérinaire de France, 168 (4): 314-319.
[16] Ahmed Nafis, Brahim Oubaha, Asma Azmani Salah, Eddine Samri, Timo Niedermeyer, Lahcen Hassani, Mustapha Barakate. (2017). Novonestmycines A et B, deux dérivés d’antifongiques non polyéniques nouvellement produits par Streptomyces sp. Z26. Journal de mycologie médicale, 27 (3): e44.
[17] El-Shatoury S., El-Kraly O., El-Kazzaz W. and Dewedar A. (2009). Antimicrobial activities of actinomycetes inhabiting Achillea fragrantissima (Family: Compositae). Egyptian Journal of Natural Toxins, 6 (2): 1-15.
[18] Intra B., Mungsuntisuk I., Nihira T., Igarashi Y. and Panbangred W. (2011). Identification of actinomycetes from plant rhizospheric soils with inhibitory activity against Colletotrichum. spp, the causative agent of anthracnose disease. BMC Research Notes, 4: 98.
[19] Gurung. T. D. Sherpa. C. Agrawal. V. P. & Lekhak. B. (2009). Isolation and Characterization of Antibacterial Actinomycetes from Soil Samples of Kalapatthar, Mount Everest Region. Nepal Journal of Science and Technology, 10: 173-182.
[20] Jose P. A., Sivakala K. K, Jebakumar S. R. D. (2013). Formulation and Statistical optimization of culture medium for improved production of antimicrobial compound by Streptomyces sp. JAJ06. Int. J. Microbiolo, 1-9.
[21] Grahovac J, Grahovac M, Dodić J, Bajić B, Balaž J. (2014). Optimization of cultivation medium for enhanced production of antifungal metabolites by Streptomyces hygroscopicus. Crop Prot, 65: 143–152.
[22] Bhosale J., Kadam T. A., Fulwad S. G., Karale M. A. and Kanse O. S. (2015). Optimization of antifungal compound production by a moderately halophilic Streptomyces werraensis HB-11. International journal of pharmaceutical sciences and research, 6 (3): 1090-99.
[23] Dulaney E. L. (1949). Observations on Streptomyces griseus, III. Carbon sources for growth and streptomycin production. Mycologia, (41): 1-10.
[24] Li T., Fan Y., Nambou K., Hu F., Imanaka T., Wei L. et al. (2015). Improvement of ansamitocin P-3 production by Actinosynnema mirum with fructose as the sole carbon source. Appl. Biochem. Biotechnol., 175: 2845–2856.
[25] Forar L. R., Ali E., Mahmoud S., Bengraa C., Hacenae H. (2007). Screening, isolation and characterization of novel antimicrobial producing actinomycetes strain RAF 10. Biotechnology, 6: 489-496.
[26] Augustine S. K., Bhavsar S. P. and Kapadnis B. P. (2005). Production of a growth dependent metabolite active against dermatophytes by Streptomyces rochei Indian Journal of Medical Research, 121: 164-170.
[27] Vijayakumar R., Panneerselvam K., Muthukumar C., Thajuddin N., Panneerselvam A. and Saravanamuthu R. (2012). Optimization of antimicrobial production by a marine actinomycete Streptomyces afghaniensis VPTS3-1 isolated from Palk Strait, East Coast of India. Indian Journal of Microbiology, 52: 230-239.
[28] Kim H., Kim S. W., and Hong S. I. (1999). An integrated fermentation–separation process for the production of red pigment by Serratia sp KH-95. Process Biochemistry, 35: 485-490.
[29] Thompson C. J., Fink D., and Nguyen L. D. (2002). Principles of microbial alchemy: insights from the Streptomyces coelicolor genome sequence. Gen. Biol., 3 (7): 10201-10204.
[30] Dharmaraj S., Ashokkumar B. and Dhevendaran K. (2009). Food-grade pigments from Streptomyces sp isolated from the marine sponge Callyspongia diffusa. Food Research International, 42: 487-492.
[31] Christhudas N. I. V. S., Kumar P. P., Agastian P. (2012). Antimicrobial activity and HPLC analysis of tropane alkaloids in Streptomyces spp. isolated from Datura stramonium L. Asian Journal of Pharmaceutical and clinical research, 5 (4): 278-282.
[32] Abdessamad Debbab, Amal H. Aly, Ruangelie Edrada-Ebel, Victor Wray, Alexander Pretsch, Gennaro Pescitelli, Tibor Kurtan, Peter Proksch. (2012). New Anthracene Derivatives – Structure Elucidation and Antimicrobial Activity. European journal of organic chemistry, 7: 1351-1359.
[33] Taechowisan T., Lu C., Shen Y., Lumyong S. (2005). Secondary metabolites from endophytic Streptomyces aureofaciens CMUAc130 and their antifungal activity. Microbiology, 151 (5): 1691-5.
[34] Ping Cai, Fangming Kong, Pamela Fink, Mark E. Ruppen, R. Thomas Williamson and Tabei Keiko. (2007). Polyene antibiotics from Streptomyces mediocidicus. Journal of natural products, 70 (2): 215-219.
[35] Praveen Kumar Jain and P. C. Jain. (2007). Isolation, characterization and antifungal activity of Streptomyces sampsonii GS 1322. Indian Journal of Experimental Biology, (45): 203-206.
Cite This Article
  • APA Style

    Herivony Onja Andriambeloson, Bodoharinjara Léontine Rafalisoa, Rigobert Andrianantenaina, Andriamiliharison Jean Rasamindrakotroka, Rado Rasolomampianiana. (2019). Effect of Streptomyces sp 3400 JX826625 Metabolites on Multidrug Resistant Candida albicans Development and Chemical Characterization of Antifungal Metabolites. American Journal of Biomedical and Life Sciences, 7(6), 164-173. https://doi.org/10.11648/j.ajbls.20190706.17

    Copy | Download

    ACS Style

    Herivony Onja Andriambeloson; Bodoharinjara Léontine Rafalisoa; Rigobert Andrianantenaina; Andriamiliharison Jean Rasamindrakotroka; Rado Rasolomampianiana. Effect of Streptomyces sp 3400 JX826625 Metabolites on Multidrug Resistant Candida albicans Development and Chemical Characterization of Antifungal Metabolites. Am. J. Biomed. Life Sci. 2019, 7(6), 164-173. doi: 10.11648/j.ajbls.20190706.17

    Copy | Download

    AMA Style

    Herivony Onja Andriambeloson, Bodoharinjara Léontine Rafalisoa, Rigobert Andrianantenaina, Andriamiliharison Jean Rasamindrakotroka, Rado Rasolomampianiana. Effect of Streptomyces sp 3400 JX826625 Metabolites on Multidrug Resistant Candida albicans Development and Chemical Characterization of Antifungal Metabolites. Am J Biomed Life Sci. 2019;7(6):164-173. doi: 10.11648/j.ajbls.20190706.17

    Copy | Download

  • @article{10.11648/j.ajbls.20190706.17,
      author = {Herivony Onja Andriambeloson and Bodoharinjara Léontine Rafalisoa and Rigobert Andrianantenaina and Andriamiliharison Jean Rasamindrakotroka and Rado Rasolomampianiana},
      title = {Effect of Streptomyces sp 3400 JX826625 Metabolites on Multidrug Resistant Candida albicans Development and Chemical Characterization of Antifungal Metabolites},
      journal = {American Journal of Biomedical and Life Sciences},
      volume = {7},
      number = {6},
      pages = {164-173},
      doi = {10.11648/j.ajbls.20190706.17},
      url = {https://doi.org/10.11648/j.ajbls.20190706.17},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajbls.20190706.17},
      abstract = {The search of new antimicrobial metabolites remains until now an alternative to mitigate concerns caused by antimicrobial resistance. This work aims to demonstrate the ability of actinomycete strain (Streptomyces sp 3400 JX826625) to inhibit pathogen yeast growth (Candida albicans), isolated from a woman infected by recidivate candidiasis and to reveal chemical characteristics of the antifungal metabolites produced. Antifungal test using cylinder agar technique showed that the yeast pathogen was resistant to the nystatin 100.000 and the ketoconazole 50 while Streptomyces sp 3400 displayed activity with 25mm of inhibition zone diameter. The optimization of antifungal production parameters by the strain recapitulates that its culture on sporulation agar medium at a pH=5,13, incubated at 30°C for 7 days promoted the activity of the actinomycete; the butanol was the best solvent for antifungal metabolites extraction. Chemical investigation showed that liquid-liquid fractionation method of crude extract allowed to obtain four fractions (hexane, dichloromethane, butanol and aqueous fractions) in which butanol fraction exhibited the best antifungal activity (19mm) according to antifungal test by disk method. Separation of active compounds from this active fraction by TLC method revealed 10 bands and its bioautography showed two active compounds against the pathogen yeast of which the diameters of inhibition zone were 19mm and 10mm, respectively. Chemical screening of the butanolic fraction revealed the presence of terpenes, alkaloids, coumarins and anthracene derivatives family with colorimetry by TLC method. The recovering of active compounds by TLC preparative gave two methanolic fractions (MF1 and MF2) of which MIC and MFC were respectively 1,562µg/ml and 3,625µg/ml for MF1; 17µg/ml and 34µg/ml for MF2. The two compounds were stable in a range of temperature from 19°C to 46°C; however, a best antifungal activity was recorded at -20°C. UV- visible spectra of the two active compounds revealed that Streptomyces sp 3400 contained non-polyene and heptaene group of polyene molecules.},
     year = {2019}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Effect of Streptomyces sp 3400 JX826625 Metabolites on Multidrug Resistant Candida albicans Development and Chemical Characterization of Antifungal Metabolites
    AU  - Herivony Onja Andriambeloson
    AU  - Bodoharinjara Léontine Rafalisoa
    AU  - Rigobert Andrianantenaina
    AU  - Andriamiliharison Jean Rasamindrakotroka
    AU  - Rado Rasolomampianiana
    Y1  - 2019/12/04
    PY  - 2019
    N1  - https://doi.org/10.11648/j.ajbls.20190706.17
    DO  - 10.11648/j.ajbls.20190706.17
    T2  - American Journal of Biomedical and Life Sciences
    JF  - American Journal of Biomedical and Life Sciences
    JO  - American Journal of Biomedical and Life Sciences
    SP  - 164
    EP  - 173
    PB  - Science Publishing Group
    SN  - 2330-880X
    UR  - https://doi.org/10.11648/j.ajbls.20190706.17
    AB  - The search of new antimicrobial metabolites remains until now an alternative to mitigate concerns caused by antimicrobial resistance. This work aims to demonstrate the ability of actinomycete strain (Streptomyces sp 3400 JX826625) to inhibit pathogen yeast growth (Candida albicans), isolated from a woman infected by recidivate candidiasis and to reveal chemical characteristics of the antifungal metabolites produced. Antifungal test using cylinder agar technique showed that the yeast pathogen was resistant to the nystatin 100.000 and the ketoconazole 50 while Streptomyces sp 3400 displayed activity with 25mm of inhibition zone diameter. The optimization of antifungal production parameters by the strain recapitulates that its culture on sporulation agar medium at a pH=5,13, incubated at 30°C for 7 days promoted the activity of the actinomycete; the butanol was the best solvent for antifungal metabolites extraction. Chemical investigation showed that liquid-liquid fractionation method of crude extract allowed to obtain four fractions (hexane, dichloromethane, butanol and aqueous fractions) in which butanol fraction exhibited the best antifungal activity (19mm) according to antifungal test by disk method. Separation of active compounds from this active fraction by TLC method revealed 10 bands and its bioautography showed two active compounds against the pathogen yeast of which the diameters of inhibition zone were 19mm and 10mm, respectively. Chemical screening of the butanolic fraction revealed the presence of terpenes, alkaloids, coumarins and anthracene derivatives family with colorimetry by TLC method. The recovering of active compounds by TLC preparative gave two methanolic fractions (MF1 and MF2) of which MIC and MFC were respectively 1,562µg/ml and 3,625µg/ml for MF1; 17µg/ml and 34µg/ml for MF2. The two compounds were stable in a range of temperature from 19°C to 46°C; however, a best antifungal activity was recorded at -20°C. UV- visible spectra of the two active compounds revealed that Streptomyces sp 3400 contained non-polyene and heptaene group of polyene molecules.
    VL  - 7
    IS  - 6
    ER  - 

    Copy | Download

Author Information
  • National Centre of Environmental Research, Antananarivo, Madagascar

  • Mention of Fundamental and Applied Biochemistry, Faculty of Sciences, University of Antananarivo, Antananarivo, Madagascar

  • National Centre of Environmental Research, Antananarivo, Madagascar

  • Medical Biology Training and Research Laboratory, Faculty of Medicine, University of Antananarivo, Antananarivo, Madagascar

  • National Centre of Environmental Research, Antananarivo, Madagascar

  • Sections